HRTX - ヘロン・セラピュ―ティクス (Heron Therapeutics Inc. ) ヘロン・セラピュ―ティクス

 HRTXのチャート


 HRTXの企業情報

symbol HRTx
会社名 Heron Therapeutics Inc (ヘロン・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ヘロン・セラピューティクス(Heron Therapeutics Inc.)は癌と痛みに苦しむ患者のための医薬品の開発に従事するバイオテクノロジー企業。同社の薬品候補には、「SUSTOL」、「HTX-019」、「HTX-011」が含まれる。薬品候補のすべては、Biochronomer薬物送達技術を含む科学技術プラットフォームを利用する。中等度催吐性リスク化学療法(MEC)または高度催吐性化学療法(HEC)に関連する急性と遅延の化学療法誘発性悪心・嘔吐(CINV)の予防のために、同社はSUSTOL(グラニセトロン)徐放性注射剤を開発する。HTX-019は、ニューロキニン1(NK1)受容体アンタゴニストであるアプレピタントの静脈内製剤であり、CINVの予防のために開発される。HTX-011は、抗炎症性メロキシカムとの一定用量の組み合わせにおける局所麻酔薬ブピバカインの長期作用性製剤であり、術後疼痛の予防のために開発される。HTX-011は第2相臨床試験中である。   ヘロン・セラピュ―ティクスは米国の製薬会社。同社の独自技術のポリマ―ベ―スの薬物送達プラットフォ―ムBiochromerを使用して製品を開発する。主力製品のグラニセトロン注射「SUSTOL」は、急性遅延発症化学療法に伴う悪心・嘔吐の予防薬で、これは医薬品の活性成分の作用持続時間を延長することで効果を見込む。   Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from pain or cancer.
本社所在地 4242 Campus Point Court Suite 200 San Diego CA 92121 USA
代表者氏名 Kevin C. Tang ケヴィン・C・タング
代表者役職名 Independent Chairman of the Board
電話番号 +1 650-366-2626
設立年月日 30348
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 145人
url www.appharma.com
nasdaq_url https://www.nasdaq.com/symbol/hrtx
adr_tso
EBITDA EBITDA(百万ドル) -192.54600
終値(lastsale) 31
時価総額(marketcap) 2409762804
時価総額 時価総額(百万ドル) 2264.4
売上高 売上高(百万ドル) 47.46900
企業価値(EV) 企業価値(EV)(百万ドル) 1870.548
当期純利益 当期純利益(百万ドル) -195.29100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Heron Therapeutics Inc revenues increased from $12.1M to $28.8M. Net loss decreased 2% to $90.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in SGA decrease of 7% to $4.6M (expense) Stock-based Compensation in SGA decrease of 6% to $4.8M (expense).

 HRTXのテクニカル分析


 HRTXのニュース

   Heron Therapeutics EPS misses by $0.06, misses on revenue  2021/08/09 12:39:16 Seeking Alpha
   The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs  2021/07/29 12:15:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDAQ: RGEN ) (reacted to second-quarter results) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services, Inc. (NYSE: WST ) Translate Bio, Inc. (NASDAQ: TBIO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) 89bio, Inc. (NASDAQ: ETNB ) Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS ) Adicet Bio, Inc. (NASDAQ: ACET ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Biodesix, Inc. (NASDAQ: BDSX ) Candel Therapeutics, Inc.
   Heron Therapeutics'' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients  2021/07/22 11:19:51 Benzinga
Heron Therapeutics Inc (NASDAQ: HRTX ) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 65 years and older after bunionectomy and hernia repair. Zynrelef is an extended-release solution of bupivacaine and meloxicam indicated in adults for soft tissue or periarticular instillation to produce postsurgical Full story available on Benzinga.com
   Heron Therapeutics highlights promising data from ZYNRELEF postoperative pain trials  2021/07/21 20:29:04 Seeking Alpha
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   The Daily Biotech Pulse: Merck''s Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs  2021/07/29 12:15:52 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) (reacted to second-quarter results) Arvinas, Inc. (NASDAQ: ARVN ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioNTech SE (NASDAQ: BNTX ) (reacted to COVID-19 vaccine sales revealed by Pfizer, Inc. in its quarterly results) Cassava Sciences, Inc. (NASDAQ: SAVA ) (saw an acceleration in momentum set in motion by Alzheimer''s data release) Edwards Lifesciences Corporation (NYSE: EW ) Globus Medical, Inc. (NYSE: GMED ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Merit Medical Systems, Inc. (NASDAQ: MMSI ) Repligen Corporation (NASDAQ: RGEN ) (reacted to second-quarter results) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services, Inc. (NYSE: WST ) Translate Bio, Inc. (NASDAQ: TBIO ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 28) 89bio, Inc. (NASDAQ: ETNB ) Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS ) Adicet Bio, Inc. (NASDAQ: ACET ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) Biodesix, Inc. (NASDAQ: BDSX ) Candel Therapeutics, Inc.
   Heron Therapeutics'' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients  2021/07/22 11:19:51 Benzinga
Heron Therapeutics Inc (NASDAQ: HRTX ) has announced the online publication of a new analysis from the Phase 3 EPOCH 1 and EPOCH 2 studies evaluating Zynrelef (bupivacaine and meloxicam) in adults aged 65 years and older after bunionectomy and hernia repair. Zynrelef is an extended-release solution of bupivacaine and meloxicam indicated in adults for soft tissue or periarticular instillation to produce postsurgical Full story available on Benzinga.com
   Heron Therapeutics highlights promising data from ZYNRELEF postoperative pain trials  2021/07/21 20:29:04 Seeking Alpha
   The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street  2021/07/20 12:19:55 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated (NASDAQ: CYTK ) ( announced topline results from Cohorts 1 and 2 of the Phase 2 study of CK-274 in obstructive outflow disease in hypertrophic cardiomyopathy) Forward Pharma A/S (NASDAQ: FWP ) ResMed Inc. (NYSE: NRMD) Legend Biotech Corporation (NASDAQ: LEGN ) Moderna, Inc. (NASDAQ: MRNA ) ( extended gains on recent momentum) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 19) 4D pharma plc (NASDAQ: LBPS ) Adaptimmune Therapeutics plc (NASDAQ: ADAP ) Adverum Biotechnologies, Inc. (NASDAQ: ADVM ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA ) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Aptose Biosciences Inc. (NASDAQ: APTO ) ARCA biopharma, Inc. (NASDAQ: ABIO ) Ascendis Pharma A/S (NASDAQ: ASND ) Assembly Biosciences, Inc.
   Postoperative Pain Therapeutics market astonishing growth by 2026 : Mallinckrodt Pharmaceuticals, Pacira BioSciences, Trevena, Heron Therapeutics, Pfizer  2021/07/15 16:02:05 Tramways Monthly
The Postoperative Pain Therapeutics Market Research Report aims to provide insights that strongly demonstrate the market structure, scope, history, potential, and development perspective. By crossing through the historical and present market status, the Postoperative Pain Therapeutics market report provides authentic and reliable estimates for the forecast period. The Best part of this report is, this []
   Filbrandt Wealth Management, LLC Buys PowerShares QQQ Trust Ser 1, Novo Nordisk A/S, Berkshire ...  2021/07/08 18:38:20 GuruFocus
Related Stocks: QQQ , BRK.B , NVO , CTXS , DTE , FNDC , FNDF , SCHC , BA , VEU , LHX , XBI , HRTX , NEM ,
   Heron Therapeutics Executes Contract With Apexus For Non-opioid Option ZYNRELEF  2021/07/06 12:54:16 Business Insider Markets
(RTTNews) - Heron Therapeutics Inc. (HRTX) said that it has executed a contract for ZYNRELEF with Apexus LLC. ZYNRELEF was approved by the U.S. Food and Drug Administration on May 12, 2021 for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal
   Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF  2021/07/06 12:30:00 PR Newswire
SAN DIEGO, July 6, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it
   Heron Therapeutics launches ZYNRELEF in the U.S.  2021/07/01 13:09:11 Seeking Alpha
   Aprepitant Market 2027: Industry Growth, Competitive Analysis & Future Prospects |Heron Therapeutics, Sandoz, Glenmark Pharmaceuticals  2021/06/09 13:36:19 OpenPR
This report properly guides new entrants as well as established players to make a difference in the global Aprepitant market. It is just the right resource for any player looking to plan new strategies. LOS ANGELES, United States: The report is

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ヘロン・セラピュ―ティクス HRTX Heron Therapeutics Inc. )

 twitter  (公式ツイッターやCEOツイッターなど)